La vendita allo scoperto per Janux Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Janux Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Janux Therapeutics (NASDAQ:JANX) Azioni, Report sulle vendite allo scoperto

Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Janux Therapeutics Inc

UBS analyst Jay Sole upgrades Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) from Neutral to Buy and raises the price target from $9 to $11.

News

Upgrades

Price Target

Analyst Ratings

UBS Upgrades Hanesbrands to Buy, Raises Price Target to $11

Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.02 by 250 percent. The company reported quarterly sales of $679.800 million which beat the analyst consensus estimate of $675.280 million by 0.67 percent. This is a 2.06 percent decrease over sales of $694.115 million the same period last year.

Earnings

Earnings Beats

TITN

Titan Machinery Q3 2025 Adj. EPS $0.07 Beats $0.02 Estimate, Sales $679.800M Beat $675.280M Estimate

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) with a Buy and raises the price target from $11 to $15.

Reiteration

ETON

HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $15

Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.54 by 0.65 percent. The company reported quarterly sales of $2.53 billion which missed the analyst consensus estimate of $2.55 billion by 0.88 percent. This is a 10.53 percent increase over sales of $2.29 billion the same period last year.

Earnings Misses

BURL

Burlington Stores Q3 2024 Adj EPS $1.55 Beats $1.54 Estimate, Sales $2.53B Miss $2.55B Estimate

Citigroup analyst Anthony Pettinari downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Buy to Neutral and lowers the price target from $55 to $52.5.

Downgrades

Citigroup Downgrades Summit Materials to Neutral, Lowers Price Target to $52.5

On Monday, November 24th, U.S. markets ended the day on a positive note, with gains fueled by a sharp drop in bond yields following Scott Bessent&#8217;s nomination as U.S. Treasury Secretary appointment eased concerns over government borrowing and trade tariffs, boosting market confidence. Small- and mid-cap stocks, which had underperformed earlier, saw strong gains, further supported by the Federal Reserve&#8217;s recent rate cuts.
In contrast, energy stocks declined as oil prices fell amid ongoing discussions of a potential ceasefire between Israel and Lebanon.
In economic data, the Chicago Fed National Activity Index dropped to -0.40 in October, down from -0.27 and below expectations of -0.20. Meanwhile, the Dallas Fed&#8217;s Texas manufacturing index improved to -2.7 in November, up from -3 but slightly missing forecasts of -2.4.
Most S&amp;P 500 sectors rose, led by real estate, materials, and consumer discretionary, while energy and tech lagged.
The Dow Jones Industrial Average was up 0.99% and closed at 44,736.57, the S&amp;P 500 gained 0.30% to 5,987.40, and the Nasdaq Composite rose 0.27% to finish at 19,054.84.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 declined 0.84% and ended the session at 38,411.50, led by losses in the Power, Automobiles &amp; Parts, and Railway &amp; Bus sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 0.69% and ended the day at 8,359.40, led by losses in the Energy, Gold, and Financials sectors.</li>
<li>India&#8217;s Nifty 50 slid 0.12% to 24,192.95, while the Nifty 500 gained 0.05%, closing at 22,564.00. The decline was led by losses in the Power, Auto, and Oil and gas sectors.</li>
<li>China&#8217;s Shanghai Composite declined 0.12% to close at 3,259.76, and the Shenzhen CSI 300 fell 0.21%, finishing the day at 3,840.18.</li>
<li>Hong Kong&#8217;s Hang Seng rose 0.04% and closed the session at 19,159.20.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 0.77%.</li>
<li>Germany&#8217;s DAX fell 0.54%.</li>
<li>France&#8217;s CAC declined0.72%.</li>
<li>FTSE 100 index traded lower by 0.40%</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.97% at $69.61/bbl, and Brent was up 0.88% at $73.14/bbl.</li>
<li>Natural Gas slid 0.26% to $3.434.</li>
<li>Gold was trading higher by 0.55% at $2,657.40, Silver was up 1.02% to $30.972, and Copper fell 0.10% to $4.1550.</li>
</ul>
US Futures at 05:30 AM ET
Dow futures declined 0.04%, S&amp;P 500 futures were down 0.02% and Nasdaq 100 futures slid 0.01%.
Forex at 05:30 AM ET
The U.S. dollar index fell 0.01% to 106.82, the USD/JPY was down 0.27% to 153.80, and the USD/AUD rose 0.21% to 1.5407.
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Dip, Crude Oil And Gold Gain - Global Markets Today While US Slept

Loop Capital analyst Garik Shmois downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Buy to Hold and lowers the price target from $54 to $52.5.

Loop Capital Downgrades Summit Materials to Hold, Lowers Price Target to $52.5

Preliminary Fiscal Year 2025 Financial Guidance:
For fiscal year 2025, excluding the patch pump program, the Company expects:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Dollars in millions, except percentages and per share data</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Reported Revenues</td>
<td colspan="2">$1,093 - $1,110</td>
</tr>
<tr>
<td>Reported Revenue Growth (%)</td>
<td colspan="2">(2.7)% - (1.2)%</td>
</tr>
<tr>
<td>Impact of F/X (%)</td>
<td colspan="2">(0.6)%</td>
</tr>
<tr>
<td>Impact of Italian Payback Measure (1) (%)</td>
<td colspan="2">0.4%</td>
</tr>
<tr>
<td>Adjusted Constant Currency Revenue Growth (%)</td>
<td colspan="2">(2.5)% - (1.0)%</td>
</tr>
<tr>
<td>Adjusted Gross Margin (%)</td>
<td colspan="2">63.25% - 64.25%</td>
</tr>
<tr>
<td>Adjusted Operating Margin (%)</td>
<td colspan="2">29.00% - 30.00%</td>
</tr>
<tr>
<td>Adjusted Earnings per Diluted Share</td>
<td colspan="2">$2.70 - $2.90</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin (%)</td>
<td colspan="2">35.50% - 36.50%</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Health Care

General

EMBC

Embecta Says For Fiscal Year 2025, Excluding The Patch Pump Program, Revenues Are Expected To Be $1.093B-$1.11B Vs. Consensus Of $1.12B, With Adjusted EPS Of $2.70-$2.90 Vs. Consensus Of $2.27

CGI Achieves Microsoft-Verified Managed XDR Solution Status, Enhancing Cybersecurity Services

<ul>
<li>Low single-digit decline in net sales year-over-year</li>
<li>Adjusted EBITDA in the range of $225 million to $235 million</li>
</ul>

AMWD

American Woodmark Projects FY25 Net Sales To Decline In Low Single Digits; Adjusted EBITDA Of $225M - $235M

<ul>
<li>The Company currently expects to incur total pre-tax charges of between $35 million and $45 million in fiscal year 2025 related to the restructuring plan, consisting of between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of the patch pump program, and between $10 million and $15 million in pre-tax, non-cash charges for asset impairments and write-offs. Note, these preliminary estimates may be revised following the completion of the ongoing analysis of the expected additional pre-tax non-cash charges associated with the implementation of the restructuring plan.</li>
<li>The Company expects the restructuring plan to be substantially complete during the first half of fiscal year 2025 and expects the discontinuation of the patch pump program and organizational restructuring plan to generate annualized pre-tax cost savings of between $60 million and $65 million. Given the organizational restructuring plan, the Company has decided to postpone the previously announced Analyst &amp; Investor Day to Spring 2025.</li>
</ul>

Embecta To Discontinue Insulin Patch Pump Program And Initiate An Organizational Restructuring Plan

Buybacks

American Woodmark Board Approved An Additional $125M Authorization For Future Share Repurchases

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Cumulus Media Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>)</h3>
<ul>
<li>On Nov. 1, Cumulus Media posted worse-than-expected third-quarter results. Mary G. Berner, President and Chief Executive Officer of Cumulus Media, said, &#8220;During the third quarter, we delivered revenue and EBITDA in-line with pacing commentary and analyst estimates. Given the market challenges, we maintained our focus on what we can control. Specifically, we continued investing to drive growth in our digital businesses, including in digital marketing services which increased revenue nearly 40% in the quarter; capitalizing on areas of improvement in national and political ad spending; maximizing operating cash flow; and improving operating leverage through ongoing expense reductions.&#8221; The company's stock fell around 42% over the past month and has a <a href="https://www.benzinga.com/quote/CMLS">52-week low of $0.70</a>.</li>
<li>RSI Value: 25.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CMLS Price Action: Shares of Cumulus Media fell 3.3% to close at $0.70 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">CMLS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062901/image-272.png" alt="" class="wp-image-665108" style="width:721px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062901/image-272.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062901/image-272-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062901/image-272-768x711.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Beasley Broadcast Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>)</h3>
<ul>
<li>On Nov. 5, Beasley Broadcast Group reported a quarterly loss of $2.33 per share.  Caroline Beasley, Chief Executive Officer, said, &#8220;Beasley delivered third quarter net revenue of $58.2 million and same-station revenue growth of 0.5%, driven by strong political advertising revenue and a 11.7% increase in same-station digital revenue. The ongoing success of our digital transformation strategy continues to serve as an important offset to continued challenges in the audio advertising spot market.&#8221; The company's stock fell around 31% over the past month and <a href="https://www.benzinga.com/quote/BBGI">has a 52-week low</a> of $7.66.</li>
<li>RSI Value: 23.76</li>
<li>BBGI Price Action: Shares of Beasley Broadcast jumped 11.7% to close at $9.25 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">trend in BBGI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062957/image-273.png" alt="" class="wp-image-665109" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062957/image-273.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062957/image-273-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26062957/image-273-768x699.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Asset Entities Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>)</h3>
<ul>
<li>On Nov. 15, Asset Entities reported third-quarter revenues of $202,921, representing a year-over-year increase from $60,135. &#8220;We are thrilled to see the strong year-over-year growth in revenue, with our recent strategic acquisitions and partnerships,&#8221; stated CEO Arshia Sarkhani. &#8220;We are optimistic for what&#8217;s ahead, as we continue executing strategic acquisitions, growth initiatives, and further collaborations and partnerships.&#8221; The company's stock fell around 37% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ASST">low of $0.51.</a></li>
<li>RSI Value: 24.21</li>
<li>ASST Price Action: Shares of Asset Entities fell 9.9% to close at $0.58 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">breakout in ASST shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26063058/image-274.png" alt="" class="wp-image-665111" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26063058/image-274.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26063058/image-274-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26063058/image-274-768x716.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42174548/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

ASST

BBGI

CMLS

Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio In November

Longbow Research analyst David Macgregor downgrades Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Buy to Neutral.

Longbow Research Downgrades Summit Materials to Neutral

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) with a Buy and announces $8 price target.

INAB

HC Wainwright & Co. Reiterates Buy on IN8bio, Announces $8 Price Target

American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) reported quarterly earnings of $2.08 per share which missed the analyst consensus estimate of $2.37 by 12.24 percent. This is a 11.86 percent decrease over earnings of $2.36 per share from the same period last year. The company reported quarterly sales of $452.50 million which missed the analyst consensus estimate of $458.29 million by 1.26 percent. This is a 4.51 percent decrease over sales of $473.87 million the same period last year.

American Woodmark Q2 Adj EPS $2.08 Misses $2.37 Estimate, Sales $452.50M Miss $458.29M Estimate

Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.36 by 25 percent. The company reported quarterly sales of $286.10 million which beat the analyst consensus estimate of $277.00 million by 3.29 percent. This is a 1.49 percent increase over sales of $281.90 million the same period last year.

Embecta Q4 2024 Adj EPS $0.45 Beats $0.36 Estimate, Sales $286.10M Beat $277.00M Estimate

HC Wainwright &amp; Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and announces $8 price target.

PSTV

HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Announces $8 Price Target

Jefferies analyst Yaron Kinar downgrades Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) from Buy to Hold and raises the price target from $420 to $429.

Jefferies Downgrades Everest Group to Hold, Raises Price Target to $429

HTHT

H World Sees Q4 Revenue Growth Of 1%-5% YoY, And Also In The Range Of 1%-5% Excluding DH

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on October 24. Soumit Roy has given his Buy ...

Promising Outlook for Janux Therapeutics Ahead of Key Phase 1 Data Release

TD Cowen analyst Marc Frahm has maintained their bullish stance on JANX stock, giving a Buy rating on October 31. Marc Frahm's rating is based on p...

Promising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics' JANX007 in mCRPC Treatment

Janux Therapeutics GAAP EPS of -$0.51 misses by $0.13, revenue of $0.44M misses by $1.23M

In a report released today, Justin Zelin from BTIG maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), with a price target ...

Janux Therapeutics Inc (JANX) Receives a Buy from BTIG

Scotiabank analyst George Farmer maintained a Hold rating on Janux Therapeutics Inc (JANX – Research Report) today and set a price target of $42.00...

Janux Therapeutics Inc (JANX) Receives a Hold from Scotiabank

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Janux Therapeutics Inc (JANX – Research Report), 89b...

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Janux Therapeutics, Inc. ( ($JANX) ) has released its Q3 earnings. Here is a breakdown of the information Janux Therapeutics, Inc. presented to its...

Janux Therapeutics' Q3 Report: Financials and Progress

Jeffrey La Rosa, an analyst from Leerink Partners, has initiated a new Buy rating on Janux Therapeutics Inc (JANX). Jeffrey La Rosa's rating is bas...

Innovative TRACTr Platform and Promising Prospects for Janux Therapeutics: An Analysis of JANX007's Potential in Prostate Cancer Treatment

ARDT

BPMC

CATX

CGEM

CGON

ETNB

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SNDX

Press Releases

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Small Cap

Opinion

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Janux Therapeutics Announces Updates to Board of Directors

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Comments

Janux Therapeutics

Vendite allo scoperto

Janux Therapeutics (NASDAQ:JANX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO